



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/47, C12N 15/63, A61K 38/17</p>	A3	<p>(11) International Publication Number: WO 00/17358</p> <p>(43) International Publication Date: 30 March 2000 (30.03.00)</p>																																																																					
<table style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <p>(21) International Application Number: PCT/US99/22027</p> <p>(22) International Filing Date: 22 September 1999 (22.09.99)</p> <p>(30) Priority Data:</p> <table style="width: 100%;"> <tr> <td style="width: 30%;">60/172,221</td> <td style="width: 30%;">22 September 1998 (22.09.98)</td> <td style="width: 40%;">US</td> </tr> <tr> <td>09/233,291</td> <td>19 January 1999 (19.01.99)</td> <td>US</td> </tr> <tr> <td>Not furnished</td> <td>19 January 1999 (19.01.99)</td> <td>US</td> </tr> <tr> <td>60172,232</td> <td>19 April 1999 (19.04.99)</td> <td>US</td> </tr> </table> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications</p> <table style="width: 100%;"> <tr> <td style="width: 30%;">US</td> <td style="width: 30%;">60/172,221 (CIP)</td> <td style="width: 40%;">US</td> </tr> <tr> <td>Filed on</td> <td>22 September 1998 (22.09.98)</td> <td></td> </tr> <tr> <td>US</td> <td>09/233,291 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>19 January 1999 (19.01.99)</td> <td></td> </tr> <tr> <td>US</td> <td>Not furnished (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>19 January 1999 (19.01.99)</td> <td></td> </tr> <tr> <td>US</td> <td>60/172,232 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>19 April 1999 (19.04.99)</td> <td></td> </tr> </table> <p>(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).</p> </td> <td style="width: 50%; vertical-align: top;"> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive, #12, Mountain View, CA 94040 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). BATRA, Sajeev [US/US]; 555 El Camino Real, #709, Sunnyvale, CA 94087 (US).</p> <p>(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p> <p>(88) Date of publication of the international search report: 20 July 2000 (20.07.00)</p> </td> </tr> </table>			<p>(21) International Application Number: PCT/US99/22027</p> <p>(22) International Filing Date: 22 September 1999 (22.09.99)</p> <p>(30) Priority Data:</p> <table style="width: 100%;"> <tr> <td style="width: 30%;">60/172,221</td> <td style="width: 30%;">22 September 1998 (22.09.98)</td> <td style="width: 40%;">US</td> </tr> <tr> <td>09/233,291</td> <td>19 January 1999 (19.01.99)</td> <td>US</td> </tr> <tr> <td>Not furnished</td> <td>19 January 1999 (19.01.99)</td> <td>US</td> </tr> <tr> <td>60172,232</td> <td>19 April 1999 (19.04.99)</td> <td>US</td> </tr> </table> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications</p> <table style="width: 100%;"> <tr> <td style="width: 30%;">US</td> <td style="width: 30%;">60/172,221 (CIP)</td> <td style="width: 40%;">US</td> </tr> <tr> <td>Filed on</td> <td>22 September 1998 (22.09.98)</td> <td></td> </tr> <tr> <td>US</td> <td>09/233,291 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>19 January 1999 (19.01.99)</td> <td></td> </tr> <tr> <td>US</td> <td>Not furnished (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>19 January 1999 (19.01.99)</td> <td></td> </tr> <tr> <td>US</td> <td>60/172,232 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>19 April 1999 (19.04.99)</td> <td></td> </tr> </table> <p>(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).</p>	60/172,221	22 September 1998 (22.09.98)	US	09/233,291	19 January 1999 (19.01.99)	US	Not furnished	19 January 1999 (19.01.99)	US	60172,232	19 April 1999 (19.04.99)	US	US	60/172,221 (CIP)	US	Filed on	22 September 1998 (22.09.98)		US	09/233,291 (CIP)		Filed on	19 January 1999 (19.01.99)		US	Not furnished (CIP)		Filed on	19 January 1999 (19.01.99)		US	60/172,232 (CIP)		Filed on	19 April 1999 (19.04.99)		<p>(72) Inventors; and (75) Inventors/Applicants (for US only): TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive, #12, Mountain View, CA 94040 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). BATRA, Sajeev [US/US]; 555 El Camino Real, #709, Sunnyvale, CA 94087 (US).</p> <p>(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p> <p>(88) Date of publication of the international search report: 20 July 2000 (20.07.00)</p>																															
<p>(21) International Application Number: PCT/US99/22027</p> <p>(22) International Filing Date: 22 September 1999 (22.09.99)</p> <p>(30) Priority Data:</p> <table style="width: 100%;"> <tr> <td style="width: 30%;">60/172,221</td> <td style="width: 30%;">22 September 1998 (22.09.98)</td> <td style="width: 40%;">US</td> </tr> <tr> <td>09/233,291</td> <td>19 January 1999 (19.01.99)</td> <td>US</td> </tr> <tr> <td>Not furnished</td> <td>19 January 1999 (19.01.99)</td> <td>US</td> </tr> <tr> <td>60172,232</td> <td>19 April 1999 (19.04.99)</td> <td>US</td> </tr> </table> <p>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications</p> <table style="width: 100%;"> <tr> <td style="width: 30%;">US</td> <td style="width: 30%;">60/172,221 (CIP)</td> <td style="width: 40%;">US</td> </tr> <tr> <td>Filed on</td> <td>22 September 1998 (22.09.98)</td> <td></td> </tr> <tr> <td>US</td> <td>09/233,291 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>19 January 1999 (19.01.99)</td> <td></td> </tr> <tr> <td>US</td> <td>Not furnished (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>19 January 1999 (19.01.99)</td> <td></td> </tr> <tr> <td>US</td> <td>60/172,232 (CIP)</td> <td></td> </tr> <tr> <td>Filed on</td> <td>19 April 1999 (19.04.99)</td> <td></td> </tr> </table> <p>(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).</p>	60/172,221	22 September 1998 (22.09.98)	US	09/233,291	19 January 1999 (19.01.99)	US	Not furnished	19 January 1999 (19.01.99)	US	60172,232	19 April 1999 (19.04.99)	US	US	60/172,221 (CIP)	US	Filed on	22 September 1998 (22.09.98)		US	09/233,291 (CIP)		Filed on	19 January 1999 (19.01.99)		US	Not furnished (CIP)		Filed on	19 January 1999 (19.01.99)		US	60/172,232 (CIP)		Filed on	19 April 1999 (19.04.99)		<p>(72) Inventors; and (75) Inventors/Applicants (for US only): TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive, #12, Mountain View, CA 94040 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). BATRA, Sajeev [US/US]; 555 El Camino Real, #709, Sunnyvale, CA 94087 (US).</p> <p>(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p> <p>(88) Date of publication of the international search report: 20 July 2000 (20.07.00)</p>																																		
60/172,221	22 September 1998 (22.09.98)	US																																																																					
09/233,291	19 January 1999 (19.01.99)	US																																																																					
Not furnished	19 January 1999 (19.01.99)	US																																																																					
60172,232	19 April 1999 (19.04.99)	US																																																																					
US	60/172,221 (CIP)	US																																																																					
Filed on	22 September 1998 (22.09.98)																																																																						
US	09/233,291 (CIP)																																																																						
Filed on	19 January 1999 (19.01.99)																																																																						
US	Not furnished (CIP)																																																																						
Filed on	19 January 1999 (19.01.99)																																																																						
US	60/172,232 (CIP)																																																																						
Filed on	19 April 1999 (19.04.99)																																																																						
<p>(54) Title: HUMAN CHAPERONE PROTEINS</p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 5%; text-align: right;">1</td> <td style="width: 85%; border: 1px solid black;">MAAAALRSGWCRCPRRCLGSGIQFLSSHNLPHGST</td> <td style="width: 10%; text-align: left;">1556139</td> </tr> <tr> <td style="text-align: right;">1</td> <td style="border: 1px solid black;">MAAAARLRGLGWCRCPRRCLGSGIQFLSSHNLPHGSS</td> <td style="text-align: left;">g2351410</td> </tr> <tr><td colspan="3"> </td></tr> <tr> <td style="text-align: right;">36</td> <td style="border: 1px solid black;">YQMRPFGGELPLSKSYSSGNRKGFSLGLLDNVKQE</td> <td style="text-align: left;">1556139</td> </tr> <tr> <td style="text-align: right;">36</td> <td style="border: 1px solid black;">YQISIRPGRELTLTKSYSSSGSRKGFSLGLLDNITKQE</td> <td style="text-align: left;">g2351410</td> </tr> <tr><td colspan="3"> </td></tr> <tr> <td style="text-align: right;">71</td> <td style="border: 1px solid black;">LAKNKEMKESIKKFRDEARRLEESDVLQEARRKYK</td> <td style="text-align: left;">1556139</td> </tr> <tr> <td style="text-align: right;">71</td> <td style="border: 1px solid black;">LAKNKEMKESIKKFRDEAKKLEESDALQEARRKYK</td> <td style="text-align: left;">g2351410</td> </tr> <tr><td colspan="3"> </td></tr> <tr> <td style="text-align: right;">106</td> <td style="border: 1px solid black;">TIESETVRTSEVLRKKLGELTGTVKESLHEVSKSD</td> <td style="text-align: left;">1556139</td> </tr> <tr> <td style="text-align: right;">106</td> <td style="border: 1px solid black;">SIESETVRTSEAIKKKKLGELTGTVKESLDDEVSKSD</td> <td style="text-align: left;">g2351410</td> </tr> <tr><td colspan="3"> </td></tr> <tr> <td style="text-align: right;">141</td> <td style="border: 1px solid black;">LGRKIKEGVEEAAKTAQSAESVSKGGEKLGRTAA</td> <td style="text-align: left;">1556139</td> </tr> <tr> <td style="text-align: right;">141</td> <td style="border: 1px solid black;">LGRKIKEGVEEAARRTAQSAESVSKSGEKLGRKTA</td> <td style="text-align: left;">g2351410</td> </tr> <tr><td colspan="3"> </td></tr> <tr> <td style="text-align: right;">176</td> <td style="border: 1px solid black;">FRALSQGVESVKKKEIDDSVLGQTGPYRRPQRLRKR</td> <td style="text-align: left;">1556139</td> </tr> <tr> <td style="text-align: right;">176</td> <td style="border: 1px solid black;">FKAISQGVESVKKKELDESVVLGQTGPYRRFERLRKR</td> <td style="text-align: left;">g2351410</td> </tr> <tr><td colspan="3"> </td></tr> <tr> <td style="text-align: right;">211</td> <td style="border: 1px solid black;">TEFAGDKFKKEEKVFEPNEEALGVVLHKDSKXYQQW</td> <td style="text-align: left;">1556139</td> </tr> <tr> <td style="text-align: right;">211</td> <td style="border: 1px solid black;">TEFAGAKFKKEISKVFENEEALGVVLHKDSKXYQQW</td> <td style="text-align: left;">g2351410</td> </tr> <tr><td colspan="3"> </td></tr> <tr> <td style="text-align: right;">246</td> <td style="border: 1px solid black;">KDFKENNVVFNRFFEMKMKYDESDNAFIRASRALT</td> <td style="text-align: left;">1556139</td> </tr> <tr> <td style="text-align: right;">246</td> <td style="border: 1px solid black;">KDFKDNNVVFNRFFEMKMKYDESDNVLIRASRALT</td> <td style="text-align: left;">g2351410</td> </tr> </table>			1	MAAAALRSGWCRCPRRCLGSGIQFLSSHNLPHGST	1556139	1	MAAAARLRGLGWCRCPRRCLGSGIQFLSSHNLPHGSS	g2351410				36	YQMRPFGGELPLSKSYSSGNRKGFSLGLLDNVKQE	1556139	36	YQISIRPGRELTLTKSYSSSGSRKGFSLGLLDNITKQE	g2351410				71	LAKNKEMKESIKKFRDEARRLEESDVLQEARRKYK	1556139	71	LAKNKEMKESIKKFRDEAKKLEESDALQEARRKYK	g2351410				106	TIESETVRTSEVLRKKLGELTGTVKESLHEVSKSD	1556139	106	SIESETVRTSEAIKKKKLGELTGTVKESLDDEVSKSD	g2351410				141	LGRKIKEGVEEAAKTAQSAESVSKGGEKLGRTAA	1556139	141	LGRKIKEGVEEAARRTAQSAESVSKSGEKLGRKTA	g2351410				176	FRALSQGVESVKKKEIDDSVLGQTGPYRRPQRLRKR	1556139	176	FKAISQGVESVKKKELDESVVLGQTGPYRRFERLRKR	g2351410				211	TEFAGDKFKKEEKVFEPNEEALGVVLHKDSKXYQQW	1556139	211	TEFAGAKFKKEISKVFENEEALGVVLHKDSKXYQQW	g2351410				246	KDFKENNVVFNRFFEMKMKYDESDNAFIRASRALT	1556139	246	KDFKDNNVVFNRFFEMKMKYDESDNVLIRASRALT	g2351410
1	MAAAALRSGWCRCPRRCLGSGIQFLSSHNLPHGST	1556139																																																																					
1	MAAAARLRGLGWCRCPRRCLGSGIQFLSSHNLPHGSS	g2351410																																																																					
36	YQMRPFGGELPLSKSYSSGNRKGFSLGLLDNVKQE	1556139																																																																					
36	YQISIRPGRELTLTKSYSSSGSRKGFSLGLLDNITKQE	g2351410																																																																					
71	LAKNKEMKESIKKFRDEARRLEESDVLQEARRKYK	1556139																																																																					
71	LAKNKEMKESIKKFRDEAKKLEESDALQEARRKYK	g2351410																																																																					
106	TIESETVRTSEVLRKKLGELTGTVKESLHEVSKSD	1556139																																																																					
106	SIESETVRTSEAIKKKKLGELTGTVKESLDDEVSKSD	g2351410																																																																					
141	LGRKIKEGVEEAAKTAQSAESVSKGGEKLGRTAA	1556139																																																																					
141	LGRKIKEGVEEAARRTAQSAESVSKSGEKLGRKTA	g2351410																																																																					
176	FRALSQGVESVKKKEIDDSVLGQTGPYRRPQRLRKR	1556139																																																																					
176	FKAISQGVESVKKKELDESVVLGQTGPYRRFERLRKR	g2351410																																																																					
211	TEFAGDKFKKEEKVFEPNEEALGVVLHKDSKXYQQW	1556139																																																																					
211	TEFAGAKFKKEISKVFENEEALGVVLHKDSKXYQQW	g2351410																																																																					
246	KDFKENNVVFNRFFEMKMKYDESDNAFIRASRALT	1556139																																																																					
246	KDFKDNNVVFNRFFEMKMKYDESDNVLIRASRALT	g2351410																																																																					
<p>(57) Abstract</p> <p>The invention provides human chaperone proteins (HCHP) and polynucleotides which identify and encode HCHP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HCHP.</p>																																																																							

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

Intern. Application No
PCT/US 99/22027

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/47 C12N15/63 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JUN WADA ET AL.: "Characterization of mammalian translocase of inner mitochondrial membrane (Tim44) isolated from diabetic newborn mouse kidney" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 95, no. 1, 6 January 1998 (1998-01-06), pages 144-149, XP002128903 WASHINGTON US abstract page 146, left-hand column, paragraph 3 -right-hand column, paragraph 1; figure 2 page 149, left-hand column, paragraph 2 - paragraph 4	1-8, 12-16,19
X	- & Emrod Database Entry U69898 Accession number U69898; 12 September 1997 XP002128913 the whole document -/--	9-11

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

27 January 2000

Date of mailing of the international search report

16. 05. 2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

MONTERO LOPEZ B.

INTERNATIONAL SEARCH REPORT

Internat. Application No.

PCT/US 99/22027

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>NAOTADA ISHIHARA ET AL.: "Identification of the protein import components of the rat mitochondrial inner membrane rTIM17, rTIM23, and rTIM44"</p> <p>THE JOURNAL OF BIOCHEMISTRY, vol. 123, no. 4, April 1998 (1998-04), pages 722-732, XP002071314</p> <p>abstract</p> <p>page 723, right-hand column, paragraph 2</p> <p>page 723, right-hand column, paragraph 5;</p> <p>figure 1</p>	1-8, 12-16,19
X	<p>-& Emrod Database Entry Ab006452</p> <p>Accession number AB006452; 21 August 1997</p> <p>XP002128914</p> <p>the whole document</p>	9-11
P,X	<p>BAUER M. ET AL.: "Genetic and functional characterization of the human mitochondrial inner membrane translocase"</p> <p>JOURNAL OF MOLECULAR BIOLOGY, vol. 289, no. 1, May 1999 (1999-05), pages 69-82, XP000874019</p> <p>page 70, left-hand column, last paragraph</p> <p>-right-hand column, paragraph 1</p> <p>page 70, right-hand column, paragraph 3</p> <p>-page 71, left-hand column, paragraph 1</p> <p>page 72, left-hand column, paragraph 2</p> <p>-right-hand column, paragraph 1; figure 4</p> <p>page 79, left-hand column, paragraph 2 - paragraph 3</p>	1-16,19
X	<p>-& Emhum1 Database Entry Af041254</p> <p>Accession number AF041254; 27 January 1998</p> <p>XP002128915</p> <p>the whole document</p>	9-11
P,X	<p>SABINE HOFMANN ET AL.: "Identification and characterization of the human preprotein translocase of the mitochondrial inner membrane"</p> <p>MOLECULAR BIOLOGY OF THE CELL, vol. 9, November 1998 (1998-11), page 79A</p> <p>XP000870416</p> <p>abstract</p>	1-16,19
A	<p>US 5 646 249 A (FREDERIC J. KAYE ET AL.)</p> <p>8 July 1997 (1997-07-08)</p> <p>column 4, line 37 -column 21, line 52;</p> <p>examples</p>	1-16,19

-/--

INTERNATIONAL SEARCH REPORT

Internat. Publication No

PCT/US 99/22027

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	Swissprot Database Entry Im44_Human Accession number 043615; 15 July 1999 HOFMAN S. ET AL.: "Homo sapiens translocase of the inner mitochondrial membrane (hTim44) cDNA." XP002128904 the whole document	1,2
P,X	--- R61u012 Database Entry Ai798647 Accession number AI798647; 7 July 1999 XP002128905 the whole document -----	9-11

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/22027

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 19 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2. ☒ Claims Nos.: 17, 18, 20
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

see additional sheet, subject 1.

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 17, 18, 20

Present claims 17, 18 and 20 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is not to be found, however, for any specific example of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, no search has been carried out for claims 17, 18 and 20.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:1 and variants thereof; polynucleotide encoding the same and variants thereof; expression vector and host cell comprising the same; use thereof for producing the polypeptide; antibody against the polypeptide; agonist and antagonist of the polypeptide and therapeutic use of the antagonist; pharmaceutical composition comprising the polypeptide.

2. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:2 and variants thereof; polynucleotide encoding the same and variants thereof; expression vector and host cell comprising the same; use thereof for producing the polypeptide; antibody against the polypeptide; agonist and antagonist for the polypeptide and therapeutic use of the antagonist; pharmaceutical composition comprising the polypeptide.

3. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:3 and variants thereof; polynucleotide encoding the same and variants thereof; expression vector and host cell comprising the same; use thereof for producing the polypeptide; antibody against the polypeptide; agonist and antagonist of the polypeptide and therapeutic use of the antagonist; pharmaceutical composition comprising the polypeptide.

4. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:4 and variants thereof; polynucleotide encoding the same and variants thereof; expression vector and host cell comprising the same; use thereof for producing the polypeptide; antibody against the polypeptide; agonist and antagonist for the polypeptide and therapeutic use of the antagonist; pharmaceutical composition comprising the polypeptide.

5. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:5 and variants thereof; polynucleotide encoding the same and variants thereof; expression vector and host cell comprising the same; use thereof for producing the polypeptide; antibody against the polypeptide; agonist and antagonist for the polypeptide and therapeutic use of the antagonist; pharmaceutical composition comprising the polypeptide.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

6. Claims: 1-20 partially

Polypeptide comprising sequence SEQ ID NO:6 and variants thereof; polynucleotide encoding the same and variants thereof; expression vector and host cell comprising the same; use thereof for producing the polypeptide; antibody against the polypeptide; agonist and antagonist for the polypeptide and therapeutic use of the antagonist; pharmaceutical composition comprising the polypeptide.

Information on patent family members

PCT/US 99/22027

Form PCT/ISA/210 (patent family annex) (July 1992)